Oncology News | pharmaphorum

News

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.

News

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

News

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today.

News

GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

News

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.

News

Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.